Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.7975
-0.2525 (-24.05%)
At close: Aug 8, 2025, 4:00 PM
0.7895
-0.0080 (-1.00%)
After-hours: Aug 8, 2025, 7:54 PM EDT
Blueprint Medicines Revenue
Cosmos Health had revenue of $13.71M in the quarter ending March 31, 2025, a decrease of -5.98%. This brings the company's revenue in the last twelve months to $53.55M, down -3.70% year-over-year. In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth.
Revenue (ttm)
$53.55M
Revenue Growth
-3.70%
P/S Ratio
0.32
Revenue / Employee
$359,426
Employees
149
Market Cap
22.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
COSM News
- 3 days ago - Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy - GlobeNewsWire
- 6 weeks ago - Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech - GlobeNewsWire
- 3 months ago - RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 3 months ago - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 3 months ago - Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units - GlobeNewsWire
- 3 months ago - Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq - GlobeNewsWire
- 3 months ago - Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 - GlobeNewsWire
- 4 months ago - Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million - GlobeNewsWire